News from heptares therapeutics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

05 Oct, 2017, 08:00 BST Heptares Founder Richard Henderson Receives Nobel Prize in Chemistry 2017 for Pioneering Work in Cryo-EM for Visualising Biological Structures

Heptares Therapeutics ("Heptares"), a wholly owned subsidiary of Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), is delighted that one of ...


01 Sep, 2017, 00:15 BST Heptares Enters a New Research and Drug Discovery Collaboration Under its 'Orbit' Initiative with Juntendo University

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), announces the launch of a new...


01 Sep, 2017, 00:01 BST First Subject Dosed in Phase 1 Clinical Study of Novel Selective MUSCARINIC M4 Agonist in Development to Treat Major Symptoms of Alzheimer's Disease

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), announces that the first...


13 Jul, 2017, 09:00 BST Heptares Hosts Scientific Symposium in Celebration Of 10-year Anniversary

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), hosts a scientific symposium...


28 Jun, 2017, 08:00 BST Heptares Enters a New Research and Drug Discovery Collaboration Under its "Orbit" Initiative With New York University School of Medicine

New programme focused on key GPCR target implicated in aggressive brain cancer Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of...


20 Jun, 2017, 08:00 BST Heptares Plans Relocation to Cambridge, UK

Company to create a state-of-art R&D facility on Granta Park to support growth strategy Heptares Therapeutics ("Heptares"), the leading GPCR medicine ...


31 May, 2017, 18:10 BST Heptares Solves First Full-length Structure of GLP-1 Receptor Bound to Peptide Agonist

New findings highlight complexity of receptor interactions and provide crucial insights for development of peptide and small molecule therapeutics -...


18 May, 2017, 08:00 BST Heptares' Co-Founder and Chief Scientific Officer, Fiona Marshall, Receives 2017 John Daly Lecture Award in Recognition of Her Outstanding Contribution to GPCR Drug Discovery

Heptares Therapeutics ("Heptares"), the leading GPCR medicine design and development company and wholly-owned subsidiary of Sosei Group Corporation...


18 May, 2017, 08:00 BST Heptares to Receive US$5 Million Milestone Payment From Teva

Heptares Therapeutics ("Heptares"), a wholly owned subsidiary of Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), has been notified by its ...


27 Apr, 2017, 07:30 BST Heptares Collaboration With AstraZeneca Yields New Insights to Advance Drug Discovery in Pain, Cancer and Inflammation

Novel mechanisms of action highlighted from resolved structures of PAR2 bound to antagonist molecules - research published in Nature Heptares...


05 Apr, 2017, 07:35 BST Heptares To Receive US$12 Million Milestone Payment From AstraZeneca

- AZD4635 (HTL-1071), a novel adenosine A2A receptor antagonist, reverses adenosine-mediated T-cell suppression and enhances anti-tumour immunity -...


13 Mar, 2017, 07:05 GMT Heptares Therapeutics Enters Agreement With Daiichi Sankyo to Discover and Develop Novel, Small-molecules for the Treatment of Pain

Heptares Therapeutics ("Heptares"), a wholly owned subsidiary of Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) announces that it has...


31 Jan, 2017, 09:21 GMT Heptares Enters a New Research Collaboration Under Its 'Orbit' Initiative With the University of Cambridge

New Programme Focused on Apelin Receptor in Cardiovascular Diseases Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group...


08 Dec, 2016, 08:00 GMT Heptares Scientists Solve Structure of CCR9 Chemokine Receptor Offering Unique Opportunity to Apply Structure-Based Design Across Chemokine Receptor Family

Chemokine receptor family plays key role across multiple disease areas and represents an important target for drug discovery and development...


30 Nov, 2016, 00:15 GMT Heptares to Acquire G7 Therapeutics to Extend Leadership in GPCR-Focused Drug Discovery and Development

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), announces it has signed a share ...


06 Jul, 2016, 07:42 BST Initiation of Phase 1 Clinical Study With Novel Immuno-oncology Candidate Triggers US$10 Million Milestone Payment From AstraZeneca

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), announces it has been notified...


29 Jun, 2016, 09:00 BST Heptares and Leadxpro Enter Collaboration on Powerful New Approaches to GPCR Structure Determination for Drug Discovery

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), and leadXpro AG ("leadXpro"), a ...


28 Apr, 2016, 10:05 BST Heptares Chief Scientific Officer and Co-founder - Dr Fiona Marshall - Elected as a Fellow of the Academy of Medical Sciences

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), announces that Dr Fiona...


25 Apr, 2016, 16:05 BST Heptares Scientists Solve Structures of GLP-1 and Glucagon Receptors Enabling Structure-based Design for Metabolic Disease

First structure of GLP-1 receptor in active state resolved Novel allosteric binding site in glucagon receptor identified - published in Nature...


18 Apr, 2016, 08:00 BST Heptares and Kymab Enter Strategic Collaboration to Discover, Develop and Commercialise Novel Antibody Therapeutics

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), and Kymab Limited, a leading...


04 Apr, 2016, 12:39 BST Heptares Joins Pharma Consortium Applying State of the Art Cryo-Electron Microscopy to Advance Structure Based Drug Discovery

Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation (TSE Mothers Index: 4565), announces it has partnered with ...


10 Feb, 2016, 06:30 GMT Heptares Announces Positive Results from Phase 1b Clinical Trial with HTL9936, a First-in-class Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Dementia and Schizophrenia

Demonstrates changes in brain activity, therapeutic window and M1 receptor selectivity Heptares Therapeutics ("Heptares"), the wholly-owned...


02 Feb, 2016, 09:00 GMT Heptares Launches "Orbit" Initiative - A New Collaborative Drug R&D Programme for Industry and Academia Focused on G Protein-Coupled Receptors (GPCRS)

First collaboration initiated with Imperial College London Heptares Therapeutics ("Heptares"), the wholly-owned subsidiary of Sosei Group Corporation ...


30 Nov, 2015, 10:00 GMT Heptares Enters Strategic Drug Discovery Collaboration with Pfizer Inc. Focused on GPCR Targets Across Multiple Therapeutic Areas

Heptares Therapeutics ("Heptares"), the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of...


28 Sep, 2015, 08:00 BST Heptares Awarded $5.5 Million Research & Development Grant From the US National Institute on Drug Abuse (NIDA)

Project to develop first-in-class Orexin-1 receptor antagonist for the treatment of cocaine addiction and dependence. Heptares Therapeutics...